Clinical Trials in Children

Gail D. Pearson (), Kristin M. Burns () and Victoria L. Pemberton ()
Additional contact information
Gail D. Pearson: National Heart, Lung, and Blood Institute, National Institutes of Health
Kristin M. Burns: National Heart, Lung, and Blood Institute, National Institutes of Health
Victoria L. Pemberton: National Heart, Lung, and Blood Institute, National Institutes of Health

Chapter 121 in Principles and Practice of Clinical Trials, 2022, pp 2379-2395 from Springer

Abstract: Abstract Clinical trials in children are important and challenging. Many advances in pediatric health have occurred as a result of clinical trials, ranging from the polio vaccine to chemotherapy for childhood leukemia. Nevertheless, the majority of medications prescribed to children have never been evaluated in them. Relatively recent programs to encourage testing of drugs in children have yielded important new information about pharmacokinetics and pharmacodynamics in pediatric populations, often contrary to what might have been expected. Trials are required, therefore, in order to determine not only the effects of drugs but also safe doses of medications in light of developmental changes throughout childhood. In addition, clinical trials are necessary in children because they have conditions that adults may not have. Finally, as in the case of early treatment for childhood leukemia, trials in children can help inform treatment in adults with similar conditions. In the current era, there are multiple regulations and strategies to optimize safety of pediatric participants in trials. Trial design in children follows the same principles as any other trial, although particular attention needs to be paid to burden on the child and family and understanding parental perceptions of clinical trials. Pediatric drug formulations and devices may be particularly challenging to develop.

Keywords: Clinical trials; Pediatric; IRB; DSMB; Safety; Intermediate endpoints (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-52636-2_259

Ordering information: This item can be ordered from
http://www.springer.com/9783319526362

DOI: 10.1007/978-3-319-52636-2_259

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().